Dr. McBride on the Excitement With Oral Oncolytics

Video
Conference|ASCO Annual Meeting

Ali McBride, PharmD, MS, BCPS, clinical coordinator, Hematology/Oncology, secretary, Association of Community Cancer Centers (ACCC), discusses the importance with and excitement of oral oncolytics.

Ali McBride, PharmD, MS, BCPS, clinical coordinator, Hematology/Oncology, secretary, Association of Community Cancer Centers (ACCC), discusses the importance with and excitement of oral oncolytics.

<<<

View more from the 2017 ASCO Annual Meeting

Related Videos
Angela Jia, MD, PhD, of University Hospitals
Robert Wang, MD, of Fox Chase Cancer Center
Alexander Kutikov, MD, FACS, of Fox Chase Cancer Center
Roger Li, MD, of Moffitt Cancer Center
Joshua J. Meeks, MD, PhD, of Northwestern University Feinberg School of Medicine
Neal Shore, MD, FACS, of GenesisCare USA and Carolina Urologic Research Center
Mark D. Tyson, II, MD, MPH
Pasi A. Jänne, MD, PhD, discusses an exploratory analysis from the FLAURA2 trial of osimertinib plus chemotherapy in treatment-naive, EGFR-mutant NSCLC.
Eric S. Christenson, MD
Related Content
Rebecca A. Dent, MD, MSc, of National Cancer Center Singapore and Duke-NUS Medical School

Atezolizumab Plus Chemo Misses Mark in Early-Relapsing Unresectable TNBC

May 15th 2024
Article
Breast Cancer - stock.adobe.com

Olaparib/Durvalumab/Fulvestrant Combo Meets PFS End Point in HRR-Altered or MSI ER+/HER2– Breast Cancer

May 15th 2024
Article
Peter Schmid, MD, PhD, FRCP

Frontline Atezolizumab Plus Sacituzumab Govitecan Elicits Responses in PD-L1+ Advanced TNBC

May 15th 2024
Article
Oluwaseun Orikogbo, MD

Time to Bladder Cancer Treatment Is Similar Among Black and White Patients, But Other Disparities Persist

May 6th 2024
Article
Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

May 6th 2024
Article
Antoni Vilaseca Cabo, MD, of Hospital Clínic de Barcelona

TAR-210 Demonstrates Preliminary Efficacy in FGFR-Altered Non–Muscle-Invasive Bladder Cancer

May 5th 2024
Article